Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of upadacitinib in moderate to severe hidradenitis suppurativa after anti-TNF failure
2023-503661-28-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 37
01
Overview
Phase 3, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Upadacitinib with Placebo (2 arms). Primary endpoint: HiSCR 50 at Week 16. Planned start Oct 2023; status: authorised.
02
Drugs
upadacitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2023-503661-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503661-28-00.